Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer

Absci Corporation (ABSI) and AstraZeneca have announced a collaboration to develop an AI-designed antibody for cancer treatment. Absci will utilize its generative AI technology to design a therapeutic antibody targeting a specific oncology target. AstraZeneca's commitment includes upfront funding, research and development support, milestone payments, and future royalties on product sales, reflecting confidence in Absci's approach. Absci's Integrated Drug Creation™ platform integrates generative AI with wet-lab technologies, creating a unique feedback loop. This platform aims to revolutionize drug discovery by completing the entire cycle within six weeks, optimizing multiple drug features and addressing previously challenging targets. The collaboration between Absci and AstraZeneca holds promise for accelerating innovative cancer treatments by leveraging the power of AI in drug discovery.